| Company/Division name | Bend Bioscience |
| Parent company | Bend Bioscience |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2023 |
| Year reshoring implemented or to be implemented: | 2023 |
| City reshored to: | Bend |
| State(s) reshored to: | OR |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | Pharmaceuticals for clinical trials |
| What non-domestic negative factors made offshoring less attractive? | Regulatory compliance |
| What domestic positive factors made reshoring more attractive? | Automation/technology, Better Control of Process/Delivery/Factory, Higher productivity, Manufacturing/engineering joint innovation (R&D), Proximity to customers/market |
